Integrated Multi-Modal Risk Stratification Outperforms Single-Biomarker Testing in Predicting Frontline Therapy Failure in Diffuse Large B-Cell Lymphoma: A Narrative Review of the Evidence for Decision-Point-Anchored Molecular Scoring
Abstract
Abstract Background: Diffuse Large B-Cell Lymphoma is a classification of non-Hodgkins lymphoma cancers. DLBCL is extremely difficult to consistently treat because of its heterogeneity, meaning treatment must be precise and tailored. Some methods of determining prognoses and care include the IPI, COO, Single-biomarker tests, and multi-modal artificial intelligence analyses. Objective: To perform a narrative review of the evidence for decision-point-anchored molecular scoring in order to see if Integrated Multi-Modal Risk Stratification outperforms single biomarker testing. Methods: MDPI, PubMed, and Google Scholar were searched for topics such as; Large B-Cell Lymphoma, multi-risk stratification, single-biomarker testing, frontline therapy, artificial intelligence (AI), multi-model systems, and therapy failure. All sources were found within the years 2010 - 2026. Results: Integrated Multi-Modal Risk Stratification was found to be more efficient, safe, and effective against single biomarker testing. Discussion: Frontline therapy failure is detrimental to patients suffering from Diffuse Large B-Cell Lymphoma. It can set them back weeks, causing harm to their recovery. In the past, single-biomarker testing was successful at predicting potential failures to frontline therapies. However, each type of biomarker testing had its limitations and could potentially misclassify Cells Of Origin or even miss double hit genes. However, new technology like the Integrated Multi-Modal Risk Stratification can mitigate these failings. It takes a holistic approach by using AI to evaluate not just single biomarker results, but also the size of the tumor and what it looks like. This way, it can give a much more accurate prediction of Frontline therapy failures than Single biomarker testing. Conclusion: Due to its holistic approach, Integrated Multi-Modal Risk Stratification outperforms single biomarker testing’s limited capabilities. Since it is imperative to have as accurate of a prediction for frontline therapies as possible, it is necessary for more investment in Integrated Multi-Modal Risk Stratification.